These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 22967907)
1. Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells. Tveteraas IH; Müller KM; Aasrum M; Ødegård J; Dajani O; Guren T; Sandnes D; Christoffersen T J Exp Clin Cancer Res; 2012 Sep; 31(1):72. PubMed ID: 22967907 [TBL] [Abstract][Full Text] [Related]
2. Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes. Dajani OF; Meisdalen K; Guren TK; Aasrum M; Tveteraas IH; Lilleby P; Thoresen GH; Sandnes D; Christoffersen T J Cell Physiol; 2008 Feb; 214(2):371-80. PubMed ID: 17654493 [TBL] [Abstract][Full Text] [Related]
3. Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells. Müller KM; Tveteraas IH; Aasrum M; Ødegård J; Dawood M; Dajani O; Christoffersen T; Sandnes DL BMC Cancer; 2011 Oct; 11():421. PubMed ID: 21961726 [TBL] [Abstract][Full Text] [Related]
4. Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib. Matsuo M; Sakurai H; Ueno Y; Ohtani O; Saiki I Cancer Sci; 2006 Feb; 97(2):155-62. PubMed ID: 16441427 [TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. Han C; Michalopoulos GK; Wu T J Cell Physiol; 2006 Apr; 207(1):261-70. PubMed ID: 16331686 [TBL] [Abstract][Full Text] [Related]
6. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. Liu X; Carlisle DL; Swick MC; Gaither-Davis A; Grandis JR; Siegfried JM Exp Cell Res; 2007 Apr; 313(7):1361-72. PubMed ID: 17349623 [TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. Han C; Wu T J Biol Chem; 2005 Jun; 280(25):24053-63. PubMed ID: 15855163 [TBL] [Abstract][Full Text] [Related]
8. Sphingosine 1-Phosphate-Upregulated COX-2/PGE Yang CC; Hsiao LD; Shih YF; Su MH; Yang CM Oxid Med Cell Longev; 2022; 2022():7664290. PubMed ID: 35242277 [TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. Buchanan FG; Wang D; Bargiacchi F; DuBois RN J Biol Chem; 2003 Sep; 278(37):35451-7. PubMed ID: 12824187 [TBL] [Abstract][Full Text] [Related]
10. Prostaglandin E₂ receptor EP1-mediated phosphorylation of focal adhesion kinase enhances cell adhesion and migration in hepatocellular carcinoma cells. Bai X; Wang J; Zhang L; Ma J; Zhang H; Xia S; Zhang M; Ma X; Guo Y; Rong R; Cheng S; Shu W; Wang Y; Leng J Int J Oncol; 2013 May; 42(5):1833-41. PubMed ID: 23525457 [TBL] [Abstract][Full Text] [Related]
11. PGE2/EP3/SRC signaling induces EGFR nuclear translocation and growth through EGFR ligands release in lung adenocarcinoma cells. Bazzani L; Donnini S; Finetti F; Christofori G; Ziche M Oncotarget; 2017 May; 8(19):31270-31287. PubMed ID: 28415726 [TBL] [Abstract][Full Text] [Related]
12. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Ogunwobi O; Mutungi G; Beales IL Endocrinology; 2006 Sep; 147(9):4505-16. PubMed ID: 16740977 [TBL] [Abstract][Full Text] [Related]
13. The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment. Huang P; Xu X; Wang L; Zhu B; Wang X; Xia J J Cell Mol Med; 2014 Feb; 18(2):218-30. PubMed ID: 24268047 [TBL] [Abstract][Full Text] [Related]
14. Prostaglandin E2 promotes the cell growth and invasive ability of hepatocellular carcinoma cells by upregulating c-Myc expression via EP4 receptor and the PKA signaling pathway. Xia S; Ma J; Bai X; Zhang H; Cheng S; Zhang M; Zhang L; Du M; Wang Y; Li H; Rong R; Shi F; Yang Q; Leng J Oncol Rep; 2014 Oct; 32(4):1521-30. PubMed ID: 25109834 [TBL] [Abstract][Full Text] [Related]
15. PGE2-induced hypertrophy of cardiac myocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation. Mendez M; LaPointe MC Am J Physiol Heart Circ Physiol; 2005 May; 288(5):H2111-7. PubMed ID: 15626689 [TBL] [Abstract][Full Text] [Related]
16. Multiple signaling pathways are responsible for prostaglandin E2-induced murine keratinocyte proliferation. Ansari KM; Rundhaug JE; Fischer SM Mol Cancer Res; 2008 Jun; 6(6):1003-16. PubMed ID: 18567804 [TBL] [Abstract][Full Text] [Related]
17. Prostaglandin E2 accelerates invasion by upregulating Snail in hepatocellular carcinoma cells. Zhang M; Zhang H; Cheng S; Zhang D; Xu Y; Bai X; Xia S; Zhang L; Ma J; Du M; Wang Y; Wang J; Chen M; Leng J Tumour Biol; 2014 Jul; 35(7):7135-45. PubMed ID: 24760275 [TBL] [Abstract][Full Text] [Related]
18. The involvement of the docking protein Gab1 in mitogenic signalling induced by EGF and HGF in rat hepatocytes. Aasrum M; Ødegård J; Sandnes D; Christoffersen T Biochim Biophys Acta; 2013 Dec; 1833(12):3286-3294. PubMed ID: 24126105 [TBL] [Abstract][Full Text] [Related]
19. Antagonism of the prostaglandin E2 EP1 receptor in MDCK cells increases growth through activation of Akt and the epidermal growth factor receptor. Taub M; Parker R; Mathivanan P; Ariff MA; Rudra T Am J Physiol Renal Physiol; 2014 Sep; 307(5):F539-50. PubMed ID: 25007872 [TBL] [Abstract][Full Text] [Related]
20. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]